Richard Batycky, PhD
Dr. Batycky has over a decade of drug development experience. Prior to co-founding Civitas, Dr. Batycky was the CSO and SVP of research & development at Pulmatrix, Inc., a pharmaceutical company developing novel therapies for treatment and prevention of infectious respiratory disease. Before Pulmatrix, he was VP of research and development for Alkermes, Inc., where he oversaw formulation development, process science, device development and analytical development. There, he was involved in the development of over 10 products across multiple delivery platforms including several approved products (Risperdal® Consta® and Vivitrol®). Prior to Alkermes, Dr. Batycky was an original employee of Advanced Inhalation Research, the original inventor of the enabling delivery platform for CVT-301, until it was acquired by Alkermes. He has served as an assistant professor of chemical engineering at the University of Alberta and he was a post-doc at Penn State University. Dr. Batycky received his PhD from MIT in chemical engineering.